Sigilon Therapeutics, Inc.
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with m…
Biotechnology
US, Cambridge [HQ]
Lobbying Analysis
Lobbying · US Senate · Influence
Sigilon Therapeutics, Inc. has no lobbying expenses in our database.
History
Download| FY | Quarter | Expense For Lobby Disclosure | LDA Reference |
|---|---|---|---|
| No data |